Blueprint Medicines Reports Fourth Quarter and Full Year 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall St futures muted; Mideast talks, US-China summit in focus
- Activist Jana Partners calls for Six Flags sale - WSJ
- Oil holds near two-week lows while diesel cracks hit record peak
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
Blueprint Medicines (BPMC) Tops Q4 EPS by 34c
February 13, 2020 7:24 AM ESTBlueprint Medicines (NASDAQ: BPMC) reported Q4 EPS of ($1.35), $0.34 better than the analyst estimate of ($1.69). Revenue for the quarter came in at $51.5 million versus the consensus estimate of $26.07 million.
For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.
... More